Daiichi Sankyo/Luitpold Submit Injectafer For Iron Deficiency Anemia
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's U.S. subsidiary Luitpold Pharmaceuticals announced May 14 that it has submitted an NDA for Injectafer (ferric carboxymaltose), an intravenous iron replacement product for iron deficiency anemia